Catalyst Biosciences Hosts Research & Development Day Focused on Factor VIIa and Factor IX Hemophilia Programs
18 déc. 2018 12h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address...
Catalyst Biosciences to Host a Research & Development Day Focused on Factor VIIa and Factor IX Hemophilia Programs
10 déc. 2018 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address...
Catalyst Biosciences Announces Updated Positive Interim Data from Its Phase 2/3 Study of Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors
01 déc. 2018 12h00 HE
|
Catalyst Biosciences, Inc.
Results demonstrate efficacy of subcutaneous prophylaxis with MarzAA, Catalyst’s high potency engineered FVIIa Data presented at 60th American Society of Hematology Annual Meeting & Exposition ...
Catalyst Biosciences Announces Presentation at the 60th American Society of Hematology Annual Meeting & Exposition
02 nov. 2018 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address...
Catalyst Biosciences Reports Third Quarter Operating & Financial Results and Provides a Corporate Update
01 nov. 2018 08h00 HE
|
Catalyst Biosciences, Inc.
Presented Updated Positive Interim Data from the Phase 2/3 Study of Marzeptacog Alfa (Activated) (FVIIa) at Two Scientific Meetings Published Data from Phase 1 Study of Marzeptacog Alfa (Activated)...
Catalyst Biosciences Receives A Notice of Allowance from The Japan Patent Office Covering Modified Factor X Polypeptides
24 oct. 2018 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address...
Catalyst Biosciences to Present at Two Upcoming Healthcare Investor Conferences
25 sept. 2018 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address...
Catalyst Biosciences Announces Publication of Marzeptacog Alfa (Activated) Phase 1 Data in The Journal of Thrombosis and Haemostasis
04 sept. 2018 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address...
Catalyst Biosciences to Present at H.C. Wainwright & Co. 20th Annual Global Investment Conference
30 août 2018 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address...
Catalyst Biosciences Announces Updated Positive Interim Data at the 2018 Hemophilia Drug Development Summit
15 août 2018 08h00 HE
|
Catalyst Biosciences, Inc.
Data demonstrates continued efficacy of marzeptacog alfa (activated) in two additional subjects SOUTH SAN FRANCISCO, Calif., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc....